Journal of Clinical Oncology
Articles in this Issue
Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases.
4050 Background: Liver metastases contribute to immunotherapeutic resistance and unfavorable outcomes. Transarterial chemoembolization (TACE) may alter th...
Clinical validation of Northstar Response for monitoring mono- and combination immunotherapy efficacy in a multi-cancer cohort.
e14548 Background: Methylated circulating tumor DNA (ctDNA) enables non-invasive, real-time treatment response monitoring compared to conventional imaging...
Circulating tumor DNA and its correlation with survival in hormone receptor positive HER2-negative stages I-III breast cancer: A systematic review.
e15035 Background: Hormone receptor-positive (HR+) HER2-negative (-) breast cancer comprises the majority of breast cancer cases. Neoadjuvant and adjuvant...
The safety, tolerability, and efficacy of BRY812 in patients with advanced solid tumors: Preliminary results from the phase I clinical study.
3021 Background: Antibody-conjugated drugs (ADCs) have demonstrated outstanding clinical efficacy in treating a wide range of solid tumors as well as hema...
High-dose 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) chemoembolization for treatment-naïve patients with limited uveal melanoma hepatic metastases.
9550 Background: Nearly 50% of patients with uveal melanoma (UM) develop metastases with the liver being the primary site of disease in > 90% of cases....
Disparities in breast cancer screening for the Brazilian Unified Health System (SUS): A warning of the need to change public policies.
1528 Background: Breast cancer is the most prevalent form of cancer in Brazilian women, contributing significantly to cancer-related mortality, particular...
Sunburst plot: A tool for interpretation and prediction of inter-reader variability relationships in BICR studies.
e13690 Background: Blinded independent central review (BICR) is recommended by the USFDA to minimize evaluation bias and improve imaging assessment consis...
Unveiling the differences in tumor immune microenvironment between <i>KRAS</i> -wildtype and <i>KRAS</i> -mutant pancreatic ductal adenocarcinoma.
4154 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a dismal prognosis despite advances in treatment. PDAC is char...
Comparison of a 3-component genomic instability score to individual biomarker scores in classifying homologous recombination deficiency.
e15165 Background: Ovarian tumors with defects in the homologous recombination (HR) pathway have improved treatment response to DNA-damaging agents. HR de...
Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies.
3549 Background: Systemic therapy recommendations for young-onset colorectal cancer (YOCRC), CRC diagnosed at < 50 years old, are similar for late-onse...
Using large language models to assess adherence to ASCO patient-oncologist communication standards.
12105 Background: The American Society of Clinical Oncology (ASCO) convened a multidisciplinary panel resulting in patient-oncologist communication guidel...
AI-enhanced literature review: Comparing advanced pancreatic and gastric cancer trial outcomes by performance status.
e16427 Background: Clinical trials have traditionally limited enrollment to patients with ECOG Status 0-1, representing patients with relatively better pr...
<i>ESR1</i> mutations and associated alterations in patients with estrogen receptor (ER+), HER2-positive (HER2+) breast cancers at diagnosis of metastatic disease (mBC).
e13035 Background: Activating mutations in the ER, encoded by the ESR1 gene (ESR1 mt ), result in a consti...
Detection of methylated MGMT using radiomic imaging: A systematic review and meta-analysis.
e14036 Background: Gliomas is an aggressive brain tumour having a poor prognosis. The methylation status of the O6-methylguanine-DNA methyltransferase (MG...
Systematic review of prognostic models for cardiomyopathy and heart failure applicable to survivors of adolescent and young adult cancer.
12037 Background: Survivors of adolescent and young adult (AYA) cancer who receive cardiotoxic chemotherapy and/or radiation are at risk of developing can...
Does Xa mark the spot? Monitoring anti-factor Xa in cancer patients receiving low molecular weight heparin.
e23065 Background: For inpatients receiving low molecular weight heparin (LMWH), monitoring anti-factor Xa levels has become a controversial topic given t...
The complementary value of ctDNA and tissue NGS in lung cancer.
e20672 Background: This study compares the concordance and clinical utility of ctDNA-based plasma testing with Next-Generation Sequencing (NGS) performed...
Identifying predictors of lymphatic leak after nephrectomy using American College of Surgeons-National Surgical Quality Improvement Program Targeted Data.
e16545 Background: Chylous ascites is a rare complication of nephrectomy with a reported incidence of up to 5.9%, caused by the disruption of lymphatic ve...
Human vs. AI: A comparative effectiveness study of large language models for automated biomarker extraction.
e13605 Background: Unstructured data extraction is essential in oncology, with use cases spanning from individual patient care to system-wide applications...
Trends and disparities in palliative care utilization in advanced head and neck cancer hospitalizations.
12058 Background: Greater than 60% of Head and neck cancer (HNC) patients have advanced cancer at the time of presentation. They have unique physical and...
Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: A prospective, single-center phase 2 study.
e15541 Background: Bevacizumab plus FOLFIRI therapy is currently the standard second-line treatment for RAS-mutant metastatic colorectal cancer (mCRC); ho...
Atezolizumab plus bevacizumab in combination with platinum based chemotherapy for ovarian cancer: A systematic review and meta-analysis of randomized control trials.
e17558 Background: Ovarian cancer continues to be a major factor in cancer related morbidity and mortality worldwide. Recent developments in treatment hav...
First-line durvalumab plus chemotherapy with or without oleclumab for locally advanced or metastatic triple-negative breast cancer: SYNERGY overall survival and circulating tumor DNA analysis.
1097 Background: SYNERGY (NCT03616886) is a randomized, investigator-initiated, phase I/II trial testing if targeting the immunosuppressive adenosine path...
Efficacy and safety of ifupinostat (BEBT-908) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma: Results from an exploratory phase Ib study.
7050 Background: Ifupinostat is a dual HDAC/PI3Kα inhibitor designed to target tumor cell signaling networks by simultaneously inhibiting HDAC and PI3Kα,...
The prevalence and outcomes of ascites in patients hospitalized with pancreatic cancer: Insights from the Nationwide Inpatient Sample.
e16411 Background: Ascites is a frequent complication in cancer patients, significantly contributing to morbidity. Pancreatic cancer patients, particularl...